Tags

Type your tag names separated by a space and hit enter

Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
Expert Rev Vaccines. 2019 09; 18(9):921-933.ER

Abstract

Introduction: In Asia Pacific, most countries recommend a monovalent hepatitis B virus (HBV) vaccine dose at birth followed by primary vaccination series including three or four doses of combination vaccines against diphtheria, tetanus, and pertussis, with or without Haemophilus influenzae type b (Hib), HBV or poliomyelitis antigens. If hexavalent conjugate vaccines against diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Hib (DTPa-HBV-IPV/Hib) replace the vaccines included in the primary vaccination series, co-administration of lower-valent vaccines would be avoided but infants would receive ≥4 doses of HBV-containing vaccines before the age of 2 years. Areas covered: We searched for clinical trials conducted in the South-East Asia and Western Pacific Regions (World Health Organization geographic definition), investigating vaccination regimens with >3 doses of HBV-containing vaccines in infants, including a monovalent HBV vaccine birth dose and ≥1 dose of GSK's hexavalent DTPa-HBV-IPV/Hib vaccine. Expert opinion: The six clinical trials included in this review showed that infants who received the monovalent HBV vaccine at birth and three or four doses of DTPa-HBV-IPV/Hib vaccine achieved protective immunogenic titers with a clinically acceptable safety profile. Our results support the integration of hexavalent DTPa-HBV-IPV/Hib vaccine within existing national recommendations in the Asia Pacific region to reduce the number of injections during infancy.

Authors+Show Affiliations

Vaccines, GSK , Wavre , Belgium.Vaccines, GSK , Wavre , Belgium.Vaccines, GSK, Singapore , Singapore.Vaccines, GSK , Wavre , Belgium.Vaccines, GSK , Wavre , Belgium.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

31328999

Citation

Dolhain, Jan, et al. "Integration of Hexavalent Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B Virus, Inactivated Poliomyelitis and Haemophilus Influenzae Type B Conjugate Vaccine Within Existing National Recommendations Following a Birth Dose of Monovalent Hepatitis B Virus Vaccine: Results of a Systematic Review in the Asia Pacific Region." Expert Review of Vaccines, vol. 18, no. 9, 2019, pp. 921-933.
Dolhain J, Janssens W, Sohn WY, et al. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert Rev Vaccines. 2019;18(9):921-933.
Dolhain, J., Janssens, W., Sohn, W. Y., Dindore, V., & Mukherjee, P. (2019). Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert Review of Vaccines, 18(9), 921-933. https://doi.org/10.1080/14760584.2019.1646643
Dolhain J, et al. Integration of Hexavalent Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B Virus, Inactivated Poliomyelitis and Haemophilus Influenzae Type B Conjugate Vaccine Within Existing National Recommendations Following a Birth Dose of Monovalent Hepatitis B Virus Vaccine: Results of a Systematic Review in the Asia Pacific Region. Expert Rev Vaccines. 2019;18(9):921-933. PubMed PMID: 31328999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. AU - Dolhain,Jan, AU - Janssens,Winnie, AU - Sohn,Woo-Yun, AU - Dindore,Vasundhara, AU - Mukherjee,Piyali, Y1 - 2019/08/01/ PY - 2019/7/23/pubmed PY - 2020/7/14/medline PY - 2019/7/23/entrez KW - Combination vaccine KW - DTPa-HBV-IPV/Hib KW - South-East Asia Region KW - Western Pacific Region KW - birth vaccination KW - hepatitis B vaccine KW - hexavalent vaccine KW - vaccination schedule SP - 921 EP - 933 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 18 IS - 9 N2 - Introduction: In Asia Pacific, most countries recommend a monovalent hepatitis B virus (HBV) vaccine dose at birth followed by primary vaccination series including three or four doses of combination vaccines against diphtheria, tetanus, and pertussis, with or without Haemophilus influenzae type b (Hib), HBV or poliomyelitis antigens. If hexavalent conjugate vaccines against diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Hib (DTPa-HBV-IPV/Hib) replace the vaccines included in the primary vaccination series, co-administration of lower-valent vaccines would be avoided but infants would receive ≥4 doses of HBV-containing vaccines before the age of 2 years. Areas covered: We searched for clinical trials conducted in the South-East Asia and Western Pacific Regions (World Health Organization geographic definition), investigating vaccination regimens with >3 doses of HBV-containing vaccines in infants, including a monovalent HBV vaccine birth dose and ≥1 dose of GSK's hexavalent DTPa-HBV-IPV/Hib vaccine. Expert opinion: The six clinical trials included in this review showed that infants who received the monovalent HBV vaccine at birth and three or four doses of DTPa-HBV-IPV/Hib vaccine achieved protective immunogenic titers with a clinically acceptable safety profile. Our results support the integration of hexavalent DTPa-HBV-IPV/Hib vaccine within existing national recommendations in the Asia Pacific region to reduce the number of injections during infancy. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/31328999/Integration_of_hexavalent_diphtheria_tetanus_acellular_pertussis_hepatitis_B_virus_inactivated_poliomyelitis_and_Haemophilus_influenzae_type_b_conjugate_vaccine_within_existing_national_recommendations_following_a_birth_dose_of_monovalent_hepatitis_B_virus_vaccine:_results_of_a_systematic_review_in_the_Asia_Pacific_region_ L2 - https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1646643 DB - PRIME DP - Unbound Medicine ER -